Self-pay patients can now get discounted Wegovy at retail pharmacies: It’s a smart play on the part of Novo Nordisk to make its GLP-1 available at pharmacies where most consumers still get their prescriptions. Will rival Eli Lilly follow suit?

Weight loss drug ads are prevalent on digital media: But these ads are often misleading, and younger consumers are particularly at risk of falling for deceptive weight loss drug offerings.

GLP-1 weight loss drugs aren’t worth their high price tag: A new study gives commercial and government insurers another reason to deny GLP-1 drug coverage.

AbbVie shakes up obesity market: AbbVie’s entrance to the weight loss drug market could create more competition between Big Pharma with a vote of confidence in a GLP-1 alternative.

Novo Nordisk launches D2C platform, drops price of Wegovy for cash-pay patients: The move could start a marketing showdown—and possible price war—between Novo and Lilly.

Eli Lilly’s Oscars commercial slams unapproved drugs like compounded GLP-1s: The ad could help pharma companies rebuild trust with consumers.

Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.

The Ozempic shortage is over: We explore how an FDA decision impacts compounded weight loss drug sellers like Hims & Hers and patients who are prescribed GLP-1s.

How RFK Jr.'s HHS Secretary confirmation could impact pharma: Brands and marketers may need to recalibrate strategies for vaccine messaging, GLP-1 medication access, and drug advertising.

Everyone is talking about Hims’ Super Bowl weight loss drug ad: The reaction has been largely negative. We examine why it’s a gamble that will likely pay off for Hims.

Pharma giants report mixed earnings for GLP-1s in Q4: Supply challenges and weight loss drug market competition could pose the biggest threats to Novo and Lilly in 2025.

Consumer interaction and engagement with healthcare and pharmaceutical ads vary greatly by generation. Marketers must gain a better understanding of these differences to reach patients more effectively.

​​Hims blames drugmakers for high GLP-1 prices in Super Bowl TV spot: It’s a bold—and expensive—move for Hims, especially considering the uncertain future of compounded weight loss drugs and doctors’ growing apprehension of how these treatments are marketed and sold.

US consumers see weight loss drugs as more effective than diet, exercise: Many plan to take a GLP-1 in 2025. Marketers in the health, wellness, and fitness spaces must pounce on the opportunity to frame their offerings as a better long-term bet than weight loss drugs.

Healthcare and pharma companies will lean further into D2C in 2025: They’re cutting out health insurers and PBMs that bottleneck patient access to their products and services. But the industry’s push into D2C won’t be met without challenges.

The battle between Big Pharma and D2C weight loss drug sellers will intensify in 2025: We explore the competitive GLP-1 drug market and detail what’s at stake for drugmakers and D2C companies selling compounded weight loss medications.

Healthcare and pharma companies are embracing D2C business models to get their medications, treatments, and services to more consumers without industry middlemen restricting access. Concurrently, patients are becoming more price-conscious healthcare shoppers, propelling more D2C activity next year.

Patients overspent on GLP-1 meds by $200M in the past year: Lower prices for weight loss drugs are possible, but it’s up to stakeholders in the pharma industry to direct consumers to Rx savings tools and resources.

Trump’s healthcare picks will look to rein in GLP-1 spending: His selections to run the FDA and HHS aren’t big proponents of widespread GLP-1 use for weight loss. We explore what it could mean for the obesity drug market amid a new administration.

WeightWatchers is the latest company to offer compounded GLP-1s: Consumer demand for cheaper versions of GLP-1s is forcing even weight-loss industry legacy players to sell the meds.